Check 35,000+ stocks against 26 valuation models and 37 quality factors

Surgical Science Sweden AB (SUS) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Surgical Science Sweden AB SEK 42.20, price SEK 49.62, upside -15.0%, quality 61 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? Yes
Add to watchlist

Healthcare · SE · ISIN SE0014428512

Broad data Sep 24, 2026

Surgical Science Sweden AB

SUS · ST

Overvalued / MonitorQuality is not strong enough to offset the price risk.

!Fair value kr 42.20 · Overvalued (−15%)

!Quality 61/100

✓Healthy Growth (revenue 5y +56.8 %/yr)

!Thin margins · 5.3% net margin (TTM)

✓Low debt · generates free cash flow

✓Ranks above peers (10/13)

!Narrow moat 37/100

!Weak on valuation: 13 out of 100

!Weak on past: 5 out of 100

26 models, one by oneBear kr 29.72 to bull kr 61.77 Growth analysisrevenue history, year by year Quality 61/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Surgical Science Sweden AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range kr 23.92 – kr 324.75 · fair‑value band kr 29.72 – kr 61.77 · the kr 49.62 price screens above the kr 42.20 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Surgical Science Sweden in your weekly email

Every Wednesday you see whether Surgical Science Sweden is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Surgical Science Sweden AB (publ) develops and markets virtual reality simulators and customized training solutions for evidence-based medical training in Europe, North and South America, Asia, and internationally. The company offers Angio Mentor simulator for endovascular training; BRONCH Express, a portable version of BRONCH mentor simulator; ARTHRO Mentor for arthroscopic surgery skills acquisition; BRONCH Mentor, a simulator for optimizing bronchoscopy training; GI Mentor, a simulator for GI Endoscopy; HYST Mentor for True-To-Life diagnostic and therapeutic hysteroscopy training; URO Mentor, a virtual reality simulator for endourology training; EndoSim, a realistic scope simulator; FlexVR, a flexible and portable training platform which is designed to teach basic and advanced skills for robotic surgery; and LAP Mentor provides a wide array of laparoscopic training cases. It also provides LapSim training system comprising LapSim Haptic simulator that provides laparoscopic training; LapSim essence, a portable and ready-to-use VR simulator; and LapSim 360, which provides a high-immersion virtual reality training experience; MentorLearn, an end-to-end educational platform that makes simulation course management; and LapSim ST, a training system that prepares students for the operating room. In addition, the company offers PELVIC Mentor simulator provides anatomy and pelvic exam training; Perc Mentor suite for image-guided interventions; RobotiX Mentor for practice the motor and cognitive skills for surgeons; Simball Box, which combines with digitally collected metrics into a training tool; Spine Mentor, a training simulator for minimal invasive spine surgery; TEE Express, designed to teach Trans-Esophageal Echocardiography procedure using a TEE probe; TraumaVR, an ultimate mix of manikin and VR simulation; and Ultrasound Mentor for ultrasound training with multiple medical specialties. Surgical Science AB was founded in 1997 and is based in Gothenburg, Sweden.

Stock analysis

Surgical Science Sweden AB (SUS) currently trades at kr 49.62, while our model-based Fair Value estimate is kr 42.20, implying the stock looks roughly 17.6% overvalued today.

Valuation

Bull case: the Growth Earnings group reads highest at a median of kr 58.40 per share, and 11 of the 24 models we run sit above the kr 49.62 price.

Bear case: the Economic Profit group reads lowest at kr 23.91, and 13 of the 24 models stay below the price. Evidence for this calculation is high.

Scenario range: kr 29.72 (bear) to kr 61.77 (bull), the price of kr 49.62 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Surgical Science Sweden AB reported revenue of 992M SEK in FY2025 versus 367M SEK in FY2021, a compound +28.3%/yr. Reported net income was 66.8M SEK in FY2025, compounding −6.2%/yr from FY2021.

Key figures

Market cap 2.5B SEK (≈ $256M) · P/E ratio 48.2 · P/S ratio 3.24 · EPS (TTM) kr 1.03 · Net margin 6.7% · Return on equity 1.2% · Return on assets (EBIT) 2.9% · Operating margin 11.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades about 46% below its 52-week high and 107% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −15%, SUS screens cheaper than that median.

Fair Value models

Bear kr 29.72 Fair Value kr 42.20 Bull kr 61.77

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (kr 0.7535 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF kr 28.88 kr 35.65 kr 55.39 80

Growth DCF kr 27.82 kr 37.51 kr 52.65 79

Owner Earnings kr 43.20 kr 73.24 kr 125.67 74

All 24 models by family

DCF Models

FCF DCF kr 28.88 kr 35.65 kr 55.39 80

Owner Earnings kr 43.20 kr 73.24 kr 125.67 74

5Y Revenue Exit kr 31.48 kr 46.21 kr 77.07 71

5Y EBITDA Exit kr 43.60 kr 70.67 kr 123.82 73

5Y P/E Exit kr 31.99 kr 55.96 kr 88.51 69

10Y Revenue Exit kr 29.81 kr 51.26 kr 65.08 67

10Y EBITDA Exit kr 38.02 kr 73.49 kr 136.54 65

10Y P/E Exit kr 30.77 kr 52.19 kr 87.01 62

Earnings-Based

Graham-Dodd kr 8.90 kr 62.10 kr 87.15 63

Lynch FV kr 30.50 kr 43.57 kr 56.64 61

PEG = 1.0 kr 30.50 kr 43.57 kr 56.64 57

EPV kr 22.64 kr 23.91 kr 24.94 74

Multiples

P/E Multiple kr 21.61 kr 28.81 kr 36.01 63

P/S Multiple kr 16.70 kr 22.26 kr 27.83 58

P/B Multiple kr 16.70 kr 22.26 kr 27.83 55

EV/EBIT kr 39.28 kr 48.35 kr 57.43 66

EV/EBITDA kr 51.63 kr 64.82 kr 78.01 67

EV/Revenue kr 31.48 kr 39.81 kr 48.14 54

Asset-Based

NCAV (Graham) kr 41.87 kr 56.11 kr 83.74 54

Growth DCF

Growth DCF kr 27.82 kr 37.51 kr 52.65 79

Rev-Margin DCF kr 33.52 kr 51.09 kr 87.73 71

Economic Profit

Residual Income kr 52.16 kr 47.01 kr 30.79 71

ROIC Compounder kr 22.64 kr 23.91 kr 24.94 72

Growth Earnings

Growth-Adj P/E kr 40.88 kr 58.40 kr 75.92 67

Open the full fair value analysis →

Notify me when SUS reaches fair value

Put SUS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 61/100

Of which business quality 60 · Market factors (momentum, volatility) 48

Profitability 22

Margins and returns on capital today

Quality Growth 35

Are margins and returns improving?

Cashflow 52

Earnings quality: real cash, not paper profit

Fin. Strength 88

Balance sheet, leverage, solvency risk

Investment 99

Disciplined investing over empire-building

Low Volatility 46

Calm price path (market factor)

Momentum 67

Price trend over the last 3–12 months (market factor)

52W Momentum 19

Distance to the 52-week high (market factor)

Net Issuance 81

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 85/100

Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Revenue growth 1 year

+12.2%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+7.3%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+56.8%

Start year 2020 (pandemic). Over 10 years: +35.9% a year

Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+33.6%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.

+29.7%

Earnings growth per share plus dividend.

Earnings per share, growth per year+29.7%

Dividend (yield on the price)0.0%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.24% vs 24%, steady

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.19% → 11%

Start year 2020 (pandemic)

Growth Forecast

A lot of optimism in the price

The price assumes less growth than the company has delivered so far and more than analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+19.9%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+7.7%

Yearly sales growth analysts expect, extended to five years.

After inflation (Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about +17.6% a year for the price and +5.6% for the forecasts.

Forecast 2026 (sales)+1.1%

Forecast 2027 (sales)+11.1%

Projected 2028 (sales)+10.0%

Projected 2029 (sales)+8.9%

Projected 2030 (sales)+7.7%

SUS screens 18% overvalued. Compare with Veeva Systems Inc →

Compare Surgical Science Sweden AB with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 135 stocks

Beats the industry median on 9/12 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 61 · Above median

Fair Value upside −15% · Above median

Profitability

Return on equity (TTM) 1% · Above median

Return on assets 1% · Above median

Net margin (TTM) 5% · Above median

Operating margin (TTM) 11% · Above median

Growth and dividend

Revenue growth −6% · Bottom 25%

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/E (TTM) 48.2× · Pricier than median

P/B 0.59× · Cheapest 25%

P/S (TTM) 2.59× · Pricier than median

P/FCF 3.8× · Cheapest 25%

EV/EBITDA 13.7× · Cheaper than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)13 · sector 6

FUTURE (revenue growth)0 · sector 34

PAST (return on equity)5 · sector 4

HEALTH (low debt)100 · sector 98

DIVIDEND (yield)0 · sector 46

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Veeva Systems Inc VEEV	$260.91	$287.00	+10%
Pro Medicus Limited PME	A$161.31	A$64.50	−60%
BrightSpring Health Services, Inc BTSG	$56.55	$26.07	−54%
HealthEquity, Inc HQY	$91.75	$100.93	+10%
Hinge Health, Inc HNGE	$94.15	$51.66	−45%
10x Genomics, Inc TXG	$80.70	$21.71	−73%
Waystar Holding WAY	$25.63	$28.19	+10%
XtalPi Holdings 2228	HK$8.39	HK$1.50	−82%
Doximity, Inc DOCS	$26.51	$31.41	+18%
Privia Health Group PRVA	$19.46	$5.26	−73%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Surgical Science Sweden AB · Fair Value
kr 42.20 −18%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/SUS" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Surgical Science Sweden AB · Fair Value</span><br><b style="font-size:20px">kr 42.20</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−18%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Surgical Science Sweden AB Fair Value". https://www.fairvalue-calculator.com/stock/SUS

Frequently asked questions

Is Surgical Science Sweden AB (SUS) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of kr 42.20 versus a price of kr 49.62, about −15% upside (overvalued).

What is the fair value of SUS?

Our model-based fair value for Surgical Science Sweden AB is kr 42.20 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 49.62.

What is the quality score of SUS?

Surgical Science Sweden AB has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Surgical Science Sweden AB (SUS)?

Our model-based price target is the fair value of kr 42.20 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario kr 29.72, optimistic scenario kr 61.77. It is a calculation from audited fundamentals, not an analyst target.

What is the Surgical Science Sweden AB stock forecast for 2026?

Our models put fair value at kr 42.20, about −15% upside versus a price of kr 49.62 (overvalued). Cautious scenario kr 29.72, optimistic scenario kr 61.77. The calculation is refreshed regularly with new filings.

What is the revenue of Surgical Science Sweden AB (SUS)?

Surgical Science Sweden AB reported trailing-twelve-month revenue of about 977M SEK (latest available figure, as of Sep 24, 2026).

What growth is priced into Surgical Science Sweden AB (SUS)?

For today's price to be fair in a discounted-cash-flow model, Surgical Science Sweden AB would have to grow free cash flow by +19.9 % per year for five years (discount rate 11.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +56.8 % per year. As of Sep 24, 2026.

What discount rate (WACC) does the fair value of SUS use?

Our models discount Surgical Science Sweden AB at 11.3 %: a base by market capitalisation (micro), damped by beta 0.60, country premium for Sweden. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Surgical Science Sweden AB that is +19.9 % per year a year over ten years, using the same discount rate (11.3 %) and the same formula as our fair value.

How much growth has Surgical Science Sweden AB (SUS) delivered so far?

Over the past 5 years revenue at Surgical Science Sweden AB grew +56.8 % a year. The price currently implies +19.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Surgical Science Sweden AB (SUS) growing?

The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Surgical Science Sweden AB (+19.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Surgical Science Sweden AB (SUS)?

The free-cash-flow yield on the price is 2.69 %: that much free cash flow Surgical Science Sweden AB produces per unit of market value. When it exceeds the discount rate of our models (11.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Surgical Science Sweden AB (SUS)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Surgical Science Sweden AB it is kr 42.20 per share (as of Sep 24, 2026), against a price of kr 49.62. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).

Is Surgical Science Sweden AB stock overvalued or undervalued in 2026?

As of Sep 24, 2026, SUS trades above its calculated fair value: price kr 49.62, fair value kr 42.20, a gap of about −15% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of SUS?

No. The price is what the market pays today (kr 49.62); the fair value is what the company's own numbers justify (kr 42.20). For Surgical Science Sweden AB the two are kr 7.42 per share apart. That gap is exactly why we show both numbers side by side.

How much is Surgical Science Sweden AB worth?

The market values Surgical Science Sweden AB at about 2.5B SEK (market capitalisation, as of Sep 24, 2026). Per share that is kr 49.62; our models calculate a fair value of kr 42.20 per share.

What do the bullish and bearish scenarios say about SUS?

Our models span a range for Surgical Science Sweden AB: cautious scenario kr 29.72, base kr 42.20, optimistic kr 61.77 per share (as of Sep 24, 2026, price kr 49.62). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of SUS?

Surgical Science Sweden AB trades at a price-to-earnings ratio of 48.2 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 42.20 is built from several models across several years. Other multiples: P/B 0.6, P/S 2.6, EV/EBITDA 13.7.

How solid is the balance sheet of Surgical Science Sweden AB (SUS)?

Balance-sheet figures for Surgical Science Sweden AB (as of Sep 24, 2026): return on equity 1.2%. They feed the Quality Score of 61/100, which measures business quality independently of the share price.

How far is SUS from its 52-week high?

Surgical Science Sweden AB trades at kr 49.62, about 46% below its 52-week high of kr 91.75 and 107% above the low of kr 23.92 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of kr 42.20 is for.

Which stocks are comparable to Surgical Science Sweden AB?

From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, HealthEquity, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Surgical Science Sweden AB stock attractive at the current price?

The data as of Sep 24, 2026: price kr 49.62, calculated fair value kr 42.20 (−15%), Quality Score 61/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of SUS calculated?

We run Surgical Science Sweden AB through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 42.20, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.1 % above its aggregate fair value. Surgical Science Sweden AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Surgical Science Sweden AB (SUS)?

The closing price on Sep 23, 2026 was kr 49.62. Our model-based fair value is kr 42.20, about −15% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Surgical Science Sweden AB right now?

Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (kr 29.72 to kr 61.77) leaves room in how you read the outcome.

Key figures of Surgical Science Sweden AB

How large is the market capitalisation of Surgical Science Sweden AB (SUS)?

The market capitalisation of Surgical Science Sweden AB is 2.5B SEK (≈ $256M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Surgical Science Sweden AB (SUS)?

The price-to-sales ratio of Surgical Science Sweden AB is 3.24 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Surgical Science Sweden AB (SUS)?

Earnings per share at Surgical Science Sweden AB are kr 1.03 (price ÷ EPS = P/E 48.2). Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Surgical Science Sweden AB (SUS)?

The net margin of Surgical Science Sweden AB is 6.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Surgical Science Sweden AB (SUS)?

The return on equity (ROE) of Surgical Science Sweden AB is 1.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Surgical Science Sweden AB (SUS)?

On an EBIT basis the return on assets of Surgical Science Sweden AB is 2.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Surgical Science Sweden AB (SUS)?

The operating margin of Surgical Science Sweden AB is 11.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Surgical Science Sweden AB (SUS)?

Revenue at Surgical Science Sweden AB is growing −6.1% versus a year earlier (3y avg +7.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Surgical Science Sweden AB (SUS)?

Earnings per share at Surgical Science Sweden AB are growing −43.8% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net cash does Surgical Science Sweden AB (SUS) hold?

Surgical Science Sweden AB holds more cash than debt, 615M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Surgical Science Sweden AB in the live analysis

One click puts Surgical Science Sweden AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.